389650

KQ:389650 Korea Biotechnology
Market Cap
$391.86 Million
₩573.76 Billion KRW
Market Cap Rank
#13969 Global
#384 in Korea
Share Price
₩70600.00
Change (1 day)
+0.00%
52-Week Range
₩36000.00 - ₩98000.00
All Time High
₩98000.00
About

Next Biomedical Co.,Ltd. engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. It offers hemostatic material for endoscope; and microspheres for vascular embolization. The company was founded in 2014 and is based in Incheon, South Korea.

389650 (389650) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: 0.000x

Based on the latest financial reports, 389650 (389650) has a cash flow conversion efficiency ratio of 0.000x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-9.18 Million) by net assets (₩46.25 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

389650 - Cash Flow Conversion Efficiency Trend (2021–2024)

This chart illustrates how 389650's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

389650 Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of 389650 ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for 389650 (2021–2024)

The table below shows the annual cash flow conversion efficiency of 389650 from 2021 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩45.19 Billion ₩-1.20 Billion -0.027x -103.77%
2023-12-31 ₩-5.90 Billion ₩-4.16 Billion 0.705x -97.82%
2022-12-31 ₩-253.84 Million ₩-8.21 Billion 32.336x +3146.28%
2021-12-31 ₩5.08 Billion ₩-5.40 Billion -1.061x --